Competitor Analysis: Targeted Therapy of Hepatitis C

Publisher: La Merie Publishing
Pages: 91
Format: PDF
Type: Report
Version: Download file
Product Code: LMCA0113
Release Date: August of 2011

600.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Targeted Therapy of Hepatitis C

Product description

The present Competitive Intelligence Report about Targeted Therapy of Hepatitis C provides a competitor evaluation in the field of specifically targeted antiviral therapeutics for hepatitis C (STAT-C) as of August 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Most hepatitis C virus (HCV) infected individuals seeking treatment are chronically infected. Treatment goal is to achieve a sustained virological response (SVR), which is the absence of serum HCV RNA up to 6 months after therapy is concluded. To increase efficiency of interferon treatment, pegylated interferon alpha (peg-IFN-alpha) therapy has been supplemented with ribavirin. Combination therapy with peg-IFN-alpha and ribavirin has resulted in a further increase in treatment efficiency with 54% of HCV infected patients achieving SVR. The response and rate of SVR is dependent on the genotype of HCV with only 30% of genotype 1 infected individuals achieving SVR, whereas greater than 80% of genotype 2 or 3 achieve SVR with combination therapy. Combination therapy treatment regiments are genotype dependent and the amount of peg-IFN-α administered is dependent on the type used.

The suboptimal response has led to a shift in the investigational focus for treatment of HCV toward specifically targeted antiviral therapy for HCV agents. Moreover, pegylated IFN alpha and/or ribavirin are associated with frequent side effects and have a negative impact on the patient's quality of life.

The report includes a compilation of current active projects in research and development of molecules specifically directed against novel targets in hepatitis C. In addition, the report lists company-specific R&D pipelines of targeted therapeutics in hepatitis C. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.


  • HCV Protease Inhibitors
  • HCV RNA Polymerase Inhibitors
  • Cyclophilin Inhibitors
  • HCV NS5A Protein Inhibitors
  • HCV NS4B-RNA Binding Inhibitors
  • Therapeutic & Preventative HCV Vaccines
  • Therapeutic HCV Antibodies
  • HCV Viral Entry Inhibitors
  • HCV Replication Inhibitors
  • Novel Mechanism of Action HCV Virus & Host Cell Targets
  • TLR Agonists
  • Various
  • Corporate Targeted Hepatitis C Therapeutic R&D Pipelines
  • About La Merie

Corporate Targeted Hepatitis C Therapeutic R&D Pipelines

Achillion Pharmaceuticals
Alios Biopharma
Altor Biosciences
Anadys Pharmaceuticals
Astex Therapeutics
Avila Therapeutics
Bionor Immuno
Biotica Technology
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Can-Fite BioPharma
ChronTech Pharma
Compass Biotechnologies
Conatus Pharmaceuticals
Dynavax Technologies
Eiger Pharmaceuticals
Enanta Pharmaceuticals
Epiphany Biosciences
Gilead Sciences
GlaxoSmithKline (GSK)
Heat Biologics
Idenix Pharmaceuticals
Idera Pharmaceuticals
Intellektualniy Dialog
iTherX Pharmaceuticals
Japan Tobacco
Johnson & Johnson (J&J)
Massachusetts Biologic Laboratories (MBL)
Merck & Co
Mitsubishi Tanabe Pharma
Morningside Asia Venture
Ono Pharmaceutical
Paladin Biosciences
Peregrine Pharmaceuticals
PTC Therapeutics
Presidio Pharmaceuticals
Progenics Pharmaceuticals
Regulus Therapeutics
Rosetta Genomics
Samaritan Pharmaceuticals
Santaris Pharma
Tacere Therapeutics
TaiGen Biotechnology
Teva Pharmaceutical Industries
Vertex Pharmaceuticals

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up